Organon To Report Fourth Quarter and Full Year 2024 Results and Host Conference Call on February 13, 2025
23 Gennaio 2025 - 1:30PM
Business Wire
Organon (NYSE: OGN), a global healthcare company with a focus on
women’s health, will release its fourth quarter and full year 2024
financial results on February 13, 2025, prior to the company’s
webcast and conference call scheduled for 8:30 a.m. EST.
IPR&D and Milestones
Organon does not currently expect to record any milestone
expense in the fourth quarter of 2024.
Organon’s fourth quarter and full year 2024 results have not
been finalized and are subject to the company’s quarterly financial
statement closing procedures. There can be no assurance that actual
results will not differ from the preliminary estimates described
herein.
Accessing Fourth Quarter and Full Year 2024 Financial Results
Webcast
Interested parties may access the live call via webcast on the
Organon website at
https://www.organon.com/investor-relations/events-and-presentations/.
A replay of the webcast will be available approximately two hours
after the conclusion of the live event on the company’s
website.
Institutional investors and analysts interested in participating
in the call must register in advance by clicking on this link:
https://registrations.events/direct/Q4I5851155
Following registration, participants will receive a confirmation
email containing details on how to join the conference call,
including dial-in information and a unique passcode and registrant
ID. Pre-registration will allow participants to bypass an operator
and be placed directly into the call.
About Organon
Organon is an independent global healthcare company with a
mission to help improve the health of women throughout their lives.
Organon’s diverse portfolio offers over 70 medicines and products
in women’s health, biosimilars, and a large franchise of
established medicines across a range of therapeutic areas. In
addition to Organon’s current products, the company invests in
innovative solutions and research to drive future growth
opportunities in women’s health and biosimilars. Organon is also
pursuing opportunities to collaborate with biopharmaceutical
partners and innovators who look to commercialize their products by
leveraging Organon’s scale and agile presence in fast growing
international markets.
Organon has geographic scope with significant reach, world-class
commercial capabilities, and approximately 10,000 employees with
headquarters located in Jersey City, New Jersey.
For more information, visit http://www.organon.com and connect
with us on LinkedIn, Instagram, X (formerly known as Twitter) and
Facebook.
Cautionary Note Regarding Forward-Looking Statements
The information above reflects management’s current intentions
and expectations for the future with respect to Organon’s
anticipated charges for milestone payments and the related impact
to Organon’s GAAP and non-GAAP earnings per share, which constitute
“forward-looking statements” within the meaning of the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of
1995. These statements are subject to a number of risks,
assumptions, uncertainties and other factors, such as the
completion of Organon’s quarter-end closing process, including
review by management and the audit committee of the Organon’s board
of directors, which could result in material changes to the
preliminary estimates described herein. Organon undertakes no
obligation to publicly update any forward-looking statement,
whether as a result of new information, future events or otherwise.
Factors that could cause results to differ materially from those
described in the forward-looking statements can be found in
Organon’s filings with the Securities and Exchange Commission
("SEC"), including Organon’s most recent Annual Report on Form 10-K
and subsequent SEC filings, available at the SEC’s Internet site
(www.sec.gov).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250123418875/en/
Organon Media Contacts:
Karissa Peer (614) 314-8094
Kate Vossen (732) 675-8448
Organon Investor Contacts:
Jennifer Halchak (201) 275-2711
Renee McKnight (551) 204-6129
Grafico Azioni Organon (NYSE:OGN)
Storico
Da Gen 2025 a Feb 2025
Grafico Azioni Organon (NYSE:OGN)
Storico
Da Feb 2024 a Feb 2025